login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
PERSONALIS INC (PSNL) Stock News
USA
- NASDAQ:PSNL -
US71535D1063
-
Common Stock
9.64
USD
+0.13 (+1.37%)
Last: 10/31/2025, 8:08:48 PM
9.65
USD
+0.01 (+0.1%)
After Hours:
10/31/2025, 8:08:48 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
PSNL Latest News, Press Relases and Analysis
All
Press Releases
11 days ago - By: Personalis, Inc.
Personalis to Announce Third Quarter 2025 Financial Results
16 days ago - By: Personalis, Inc.
Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing
2 months ago - By: Personalis, Inc.
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 months ago - By: The Motley Fool
Personalis (PSNL) Q2 Revenue Falls 24%
3 months ago - By: Benzinga
- Mentions:
AFG
CXDO
YUM
PACK
...
Earnings Scheduled For August 5, 2025
2 months ago - By: Personalis, Inc.
CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test
2 months ago - By: Personalis, Inc.
Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing
2 months ago - By: Personalis, Inc.
Personalis to Participate in Upcoming Investor Conferences
3 months ago - By: Zacks Investment Research
Down 27.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Personalis (PSNL)
6 months ago - By: Benzinga
Analyst Expectations For Personalis's Future
3 months ago - By: Zacks Investment Research
After Plunging 30.5% in 4 Weeks, Here's Why the Trend Might Reverse for Personalis (PSNL)
3 months ago - By: Zacks Investment Research
All You Need to Know About Personalis (PSNL) Rating Upgrade to Buy
3 months ago - By: Personalis, Inc.
Personalis Reports Second Quarter 2025 Financial Results
3 months ago - By: Personalis, Inc.
Personalis to Announce Second Quarter 2025 Financial Results
4 months ago - By: Personalis, Inc.
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 months ago - By: Yahoo Finance
- Mentions:
TEM
BAC
Tempus AI, Inc. (TEM) and Personalis Join Forces to Take on Colorectal Cancer
4 months ago - By: Personalis, Inc.
Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients
5 months ago - By: Personalis, Inc.
Personalis’ NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO
5 months ago - By: Personalis, Inc.
New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse
5 months ago - By: Personalis, Inc.
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection
6 months ago - By: Personalis, Inc.
Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference
6 months ago - By: Zacks Investment Research
- Mentions:
TSHA
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
6 months ago - By: Personalis, Inc.
Personalis Reports First Quarter 2025 Financial Results
Please enable JavaScript to continue using this application.